Baidu
map

BJC:HER2/Ki-67阳性乳腺癌保乳术后局部复发风险较高

2012-02-27 MedSci MedSci原创

 《英国癌症杂志》(British Journal of Cancer)近期发表的一项研究表明,HER2/neu阳性/Ki-67阳性乳腺原位导管癌(DCIS)女性患者保乳手术后局部复发风险较高。   该研究共纳入了1982~2000年接受乳腺癌保乳术治疗的213例DCIS患者,其中141例仅接受保乳手术,72例同时接受了术后放疗。   研究采用免疫组化法对DCIS

 《英国癌症杂志》(British Journal of Cancer)近期发表的一项研究表明,HER2/neu阳性/Ki-67阳性乳腺原位导管癌(DCIS)女性患者保乳手术后局部复发风险较高。

  该研究共纳入了1982~2000年接受乳腺癌保乳术治疗的213例DCIS患者,其中141例仅接受保乳手术,72例同时接受了术后放疗。

  研究采用免疫组化法对DCIS组织的9种生物标志物(雌激素受体、孕激素受体、Ki-67、p53、p21、细胞周期蛋白D1、HER2/neu、钙粒蛋白和psoriasin)进行检测,并评估其与肿瘤复发的关联。

  结果显示,仅接受保乳手术治疗者和接受保乳手术+放疗者10年复发率分别为36%和18%。HER2/neu阳性/Ki-67阳性与DCIS局部复发风险升高显著相关,但与肿瘤分级和患者年龄无关。但上述9种生物标志物对侵袭性复发均无预测价值。

  相关链接:HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905421, encodeId=79721905421de, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Feb 06 04:07:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694024, encodeId=0991169402419, content=<a href='/topic/show?id=347d104861a' target=_blank style='color:#2F92EE;'>#Ki-67#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10486, encryptionId=347d104861a, topicName=Ki-67)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=497929536612, createdName=zhzhxiang, createdTime=Sat Oct 13 06:07:00 CST 2012, time=2012-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928272, encodeId=89e719282e27f, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Jul 02 01:07:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405623, encodeId=16ec14056230c, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Feb 29 14:07:00 CST 2012, time=2012-02-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905421, encodeId=79721905421de, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Feb 06 04:07:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694024, encodeId=0991169402419, content=<a href='/topic/show?id=347d104861a' target=_blank style='color:#2F92EE;'>#Ki-67#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10486, encryptionId=347d104861a, topicName=Ki-67)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=497929536612, createdName=zhzhxiang, createdTime=Sat Oct 13 06:07:00 CST 2012, time=2012-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928272, encodeId=89e719282e27f, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Jul 02 01:07:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405623, encodeId=16ec14056230c, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Feb 29 14:07:00 CST 2012, time=2012-02-29, status=1, ipAttribution=)]
    2012-10-13 zhzhxiang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905421, encodeId=79721905421de, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Feb 06 04:07:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694024, encodeId=0991169402419, content=<a href='/topic/show?id=347d104861a' target=_blank style='color:#2F92EE;'>#Ki-67#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10486, encryptionId=347d104861a, topicName=Ki-67)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=497929536612, createdName=zhzhxiang, createdTime=Sat Oct 13 06:07:00 CST 2012, time=2012-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928272, encodeId=89e719282e27f, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Jul 02 01:07:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405623, encodeId=16ec14056230c, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Feb 29 14:07:00 CST 2012, time=2012-02-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905421, encodeId=79721905421de, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Feb 06 04:07:00 CST 2013, time=2013-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694024, encodeId=0991169402419, content=<a href='/topic/show?id=347d104861a' target=_blank style='color:#2F92EE;'>#Ki-67#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10486, encryptionId=347d104861a, topicName=Ki-67)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=497929536612, createdName=zhzhxiang, createdTime=Sat Oct 13 06:07:00 CST 2012, time=2012-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928272, encodeId=89e719282e27f, content=<a href='/topic/show?id=c2b04e602af' target=_blank style='color:#2F92EE;'>#局部复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47602, encryptionId=c2b04e602af, topicName=局部复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Mon Jul 02 01:07:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405623, encodeId=16ec14056230c, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed Feb 29 14:07:00 CST 2012, time=2012-02-29, status=1, ipAttribution=)]
    2012-02-29 chg122

相关资讯

HER2检测给中国的乳腺癌治疗带来挑战

 根据中国人口协会2010年发布的《中国乳腺疾病调查报告》,估计中国的乳腺癌患者数量已超过20万例。从统计学的角度来看,在全球每年新诊断出的130万例乳腺癌患者中,约15%来自中国。 中国城市中的乳腺癌患者数量逐渐增加,在年轻女性中尤其明显,这在很大程度上是由于生活方式和饮食改变,以及其他乳腺疾病(如纤维瘤)发病率增加。中国乳腺癌患者死亡增多的现象令人担忧——2010年城市女性乳

NEJM:两种HER2抑制剂联用能显著延长乳腺癌生存期

    研究发现,对于HER2阳性转移性乳腺癌,曲妥珠单抗+多西他赛+培妥珠单抗较曲妥珠单抗+多西他赛+安慰剂治疗可使患者无进展生存期(PFS)中位延长6.1个月。   CLEOPATRA(培妥珠单抗联合曲妥珠单抗临床评估)研究是一项随机、双盲、Ⅲ期国际研究,研究中808例患者被随机分为曲妥珠单抗+多西他赛联合培妥珠单抗或安慰剂治疗组。结果显示,培妥珠单抗组和安慰剂

2011圣安东尼奥乳腺癌会议热点预测

   一系列关于双膦酸盐类药物治疗乳腺癌的临床试验结果将是第34届圣安东尼奥乳腺癌会议(SABCS)的头条新闻,本次会议将于12月6~10日在得克萨斯州举行。        在本次会议上争夺关注的将有:医学研究所对环境因素和乳腺癌关系的报告,以及一系列晚期乳腺癌临床试验的新结果。       &n

NEJM:在HER2阳性乳腺癌中的曲妥珠单抗辅助治疗

  丹尼斯·斯拉门(Slamon)等 乳腺癌国际研究组成员   背景 在人类表皮生长因子受体(HER)阳性乳腺癌的辅助治疗中,曲妥珠单抗可改善(患者的)生存情况,尽管采用基于蒽环类联合疗法的方案与心脏毒性相关。我们想对一种新的含曲妥珠单抗的非蒽环类治疗方案的有效性和安全性进行评估。   方法 我们将3222名有HER2阳性早期乳腺癌的妇女随机分为3组:第一组接受多

HER2阳性乳腺癌新辅助治疗探讨

    病史及体检   患者女性,51岁,已绝经。2月前偶然触及右乳肿物,无痛及发热,未予相关检查和治疗,右乳肿块逐渐增大,于2010年1月14日入院治疗。    双乳无乳头凹陷及乳头溢液,右乳约11点可见局部皮肤凹陷征,并可触及大小约3×2 cm质硬肿物,边界欠清,活动度差,与周围皮肤轻度粘连,右腋下可触及数个肿大淋巴结,有融合,最大3×2 cm,活动度差。 辅助检查    入院后彩超检

HER2阳性早期乳腺癌化疗后辅助曲妥珠单抗有益

  《柳叶刀·肿瘤学》(Lancet Oncol)杂志最新发表的一项临床研究表明,人表皮生长因子受体2(HER2)阳性早期乳腺癌患者化疗后用曲妥珠单抗辅助治疗1年与中位随访4年时获得显著临床益处相关。   研究者评估了HERA研究中HER2阳性早期乳腺癌患者中位随访4年的无病生存和总生存。HERA研究是一项国际、多中心、随机化、开放标签的Ⅲ期临床试验,比较了HER2阳性早期乳腺癌患者在

Baidu
map
Baidu
map
Baidu
map